FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904992700> ?p ?o ?g. }

• W2904992700 abstract "Background In randomized trials (SHARP [Study of Heart and Renal Protection], IMPROVE ‐IT [Improved Reduction of Outcomes: Vytorin Efficacy International Trial]), combination of statin and ezetimibe resulted in additional reduction of cardiovascular events. The reduction was greater in patients with type 2 diabetes mellitus (T2 DM ), where elevated remnant cholesterol and high cardiovascular disease risk is characteristic. To evaluate possible causes behind these results, 40 patients eligible for cholecystectomy, randomized to simvastatin, ezetimibe, combined treatment (simvastatin+ezetimibe), or placebo treatment during 4 weeks before surgery, were studied. Methods and Results Fasting blood samples were taken before treatment start and at the end (just before surgery). Bile samples and liver biopsies were collected during surgery. Hepatic gene expression levels were assessed with qPCR . Lipoprotein, apolipoprotein levels, and content of cholesterol, cholesteryl ester, and triglycerides were measured after lipoprotein fractionation. Lipoprotein subclasses were analyzed by nuclear magnetic resonance. Apolipoprotein affinity for human arterial proteoglycans ( PG ) was measured. Biomarkers of cholesterol biosynthesis and intestinal absorption and bile lipid composition were analyzed using mass spectrometry. Combined treatment caused a statistically significant decrease in plasma remnant particles and apolipoprotein B (ApoB)/lipoprotein content of cholesterol, cholesteryl esters, and triglycerides. All treatments reduced ApoB‐lipoprotein PG binding. Simvastatin and combined treatment modified the composition of lipoproteins. Changes in biomarkers of cholesterol synthesis and absorption and bile acid synthesis were as expected. No adverse events were found. Conclusions Combined treatment caused atheroprotective changes on ApoB‐lipoproteins, remnant particles, bile components, and in ApoB‐lipoprotein affinity for arterial PG . These effects might explain the decrease of cardiovascular events seen in the SHARP and IMPROVE ‐ IT trials. Clinical Trial Registration URL : www.clinicaltrialsregister.eu . Unique identifier: 2006‐004839‐30)." @default.
• W2904992700 created "2018-12-22" @default.
• W2904992700 creator A5019916527 @default.
• W2904992700 creator A5048819643 @default.
• W2904992700 creator A5049316223 @default.
• W2904992700 creator A5054816073 @default.
• W2904992700 creator A5058639659 @default.
• W2904992700 creator A5059657261 @default.
• W2904992700 creator A5061366766 @default.
• W2904992700 creator A5063855085 @default.
• W2904992700 creator A5065527631 @default.
• W2904992700 creator A5083101667 @default.
• W2904992700 creator A5086003148 @default.
• W2904992700 date "2018-12-18" @default.
• W2904992700 modified "2023-10-09" @default.
• W2904992700 title "Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients" @default.
• W2904992700 cites W1520609538 @default.
• W2904992700 cites W1947290316 @default.
• W2904992700 cites W1964240590 @default.
• W2904992700 cites W1967315717 @default.
• W2904992700 cites W1968630986 @default.
• W2904992700 cites W1969525279 @default.
• W2904992700 cites W1969756941 @default.
• W2904992700 cites W1979788647 @default.
• W2904992700 cites W1994536728 @default.
• W2904992700 cites W2006831721 @default.
• W2904992700 cites W2009485276 @default.
• W2904992700 cites W2012070467 @default.
• W2904992700 cites W2022870329 @default.
• W2904992700 cites W2023476936 @default.
• W2904992700 cites W2033589357 @default.
• W2904992700 cites W2033746641 @default.
• W2904992700 cites W2035556394 @default.
• W2904992700 cites W2036843552 @default.
• W2904992700 cites W2038617465 @default.
• W2904992700 cites W2038751792 @default.
• W2904992700 cites W2045868118 @default.
• W2904992700 cites W2074433375 @default.
• W2904992700 cites W2079874135 @default.
• W2904992700 cites W2081597601 @default.
• W2904992700 cites W2083154566 @default.
• W2904992700 cites W2093815415 @default.
• W2904992700 cites W2094248777 @default.
• W2904992700 cites W2104005551 @default.
• W2904992700 cites W2106900555 @default.
• W2904992700 cites W2107740324 @default.
• W2904992700 cites W2108794637 @default.
• W2904992700 cites W2116108398 @default.
• W2904992700 cites W2125349227 @default.
• W2904992700 cites W2134120087 @default.
• W2904992700 cites W2149237513 @default.
• W2904992700 cites W2150100875 @default.
• W2904992700 cites W2169792817 @default.
• W2904992700 cites W2172232070 @default.
• W2904992700 cites W2259048525 @default.
• W2904992700 cites W2276876674 @default.
• W2904992700 cites W2306437724 @default.
• W2904992700 cites W2336893353 @default.
• W2904992700 cites W2342969428 @default.
• W2904992700 cites W2501649131 @default.
• W2904992700 cites W2530844910 @default.
• W2904992700 cites W2780743843 @default.
• W2904992700 cites W2810523267 @default.
• W2904992700 cites W2951646900 @default.
• W2904992700 cites W4234138812 @default.
• W2904992700 doi "https://doi.org/10.1161/jaha.118.009876" @default.
• W2904992700 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6405603" @default.
• W2904992700 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30561264" @default.
• W2904992700 hasPublicationYear "2018" @default.
• W2904992700 type Work @default.
• W2904992700 sameAs 2904992700 @default.
• W2904992700 citedByCount "19" @default.
• W2904992700 countsByYear W29049927002019 @default.
• W2904992700 countsByYear W29049927002020 @default.
• W2904992700 countsByYear W29049927002021 @default.
• W2904992700 countsByYear W29049927002022 @default.
• W2904992700 countsByYear W29049927002023 @default.
• W2904992700 crossrefType "journal-article" @default.
• W2904992700 hasAuthorship W2904992700A5019916527 @default.
• W2904992700 hasAuthorship W2904992700A5048819643 @default.
• W2904992700 hasAuthorship W2904992700A5049316223 @default.
• W2904992700 hasAuthorship W2904992700A5054816073 @default.
• W2904992700 hasAuthorship W2904992700A5058639659 @default.
• W2904992700 hasAuthorship W2904992700A5059657261 @default.
• W2904992700 hasAuthorship W2904992700A5061366766 @default.
• W2904992700 hasAuthorship W2904992700A5063855085 @default.
• W2904992700 hasAuthorship W2904992700A5065527631 @default.
• W2904992700 hasAuthorship W2904992700A5083101667 @default.
• W2904992700 hasAuthorship W2904992700A5086003148 @default.
• W2904992700 hasBestOaLocation W29049927001 @default.
• W2904992700 hasConcept C126322002 @default.
• W2904992700 hasConcept C134018914 @default.
• W2904992700 hasConcept C2776329913 @default.
• W2904992700 hasConcept C2776839432 @default.
• W2904992700 hasConcept C2778163477 @default.
• W2904992700 hasConcept C2778657065 @default.
• W2904992700 hasConcept C2780072125 @default.
• W2904992700 hasConcept C62746215 @default.
• W2904992700 hasConcept C71924100 @default.
• W2904992700 hasConcept C90924648 @default.

• next